Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03095781
Title Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

pancreatic adenocarcinoma

small intestine adenocarcinoma

hepatocellular carcinoma

colorectal adenocarcinoma

gastroesophageal junction adenocarcinoma

cholangiocarcinoma

gastric adenocarcinoma

Therapies

Pembrolizumab + XL888

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.